Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: J Immunol. 2008 Aug 1;181(3):1806–1813. doi: 10.4049/jimmunol.181.3.1806

FIGURE 5. Abrogation of CTLA4 expression on Tregs by CTLA4Ig treatment is due to decreased peripheral homeostasis.

FIGURE 5

(A) Decreased Treg frequency and CTLA4 expression in thymectomized mice treated with CTLA4Ig. BALB/c mice were thymectomized, treated with CTLA4Ig or IgG2a as in Fig. 3A, and splenic CD4 T cells harvested 3 days post-treatment (day 7). Graphs show percentage of FoxP3+ (left) and CTLA4+FoxP3+ CD4 T cells (right) among total CD4 T cells from thymectomized IgG2a- and CTLA4Ig-treated mice. Results are an average of 4 mice per group and are representative of 2 experiments. The proportion of Tregs in IgG2a- and CTLAIg-treated sham-thymectomized controls were indistinguishable from intact mice similarly treated (data not shown). (B) Long-term reduction of FoxP3+ frequencies and CTLA4 expression on FoxP3+ Tregs following CTLA4Ig treatment. BALB/c mice were treated with IgG2a or CTLA4Ig as in Fig. 3A and the proportions of FoxP3+ (left) and CTLA4+FoxP3+ CD4 T cells (right) of total CD4 T cells were determined 3–28 days post-treatment. Results are expressed as mean percentage ± SD from 4–5 mice per group.